This website will be undergoing scheduled maintenance from 4:00 pm EST on May 28th through 7:00 am EST on May 31st.
During this time users will have limited access to the site. We apologize for this inconvenience.
The Endocannabinoid System and Non-Cannabis Compounds in Clinical Practice: Palmitoylethanolamide (PEA) and Beta-Caryophyllene
Wednesday, September 15, 2021
Palmitoylethanolamide (PEA), an endogenous fatty acid amide, is clearly emerging as a new agent in the therapeutic support of patients. PEA has been shown to have a supportive effect on pain management.* This endogenous agent, which is also found in foods, has been used for decades in the Netherlands and other parts of Europe, and has now made its way to North America.
The role of the endocannabinoid system (ECS), receptors, the mechanism of action of endocannabinoids, and endocannabinoid tone
The concept of the “entourage effect” and an introduction to synergistic compounds including the terpenes, beta-caryophyllene and the long-chain fatty acid palmitoylethanolamide
Clinical evidence for PEA (palmitoylethanolamide) and beta-caryophyllene (BCP)
Accessory pathways that can be targeted for integrative approaches to support endocannabinoid tone
A .pdf file will be emailed prior to the live webinar.